Name(s) Target Manufacturer Status
Stivarga, regorafenib FLT1, KDR, FLT4, KIT, TEK, PDGFRB, PDGFRA, FGFR1, FGFR2, NTRK1, MAPK11, BRAF, ABL1, EPHA2, RAF1, RET, FRK Bayer AG FDA approved for: Colorectal Cancer, Gastrointestinal Stromal Tumor (GIST)

Clinical Trials

Trial Drug Status Phase
COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy [NCT01939223] Stivarga Recruiting Phase 3
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases [NCT02195011] SIR-Spheres, Stivarga Recruiting Phase 2
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer [NCT01298570] Camptosar, Fluorouracil, Stivarga, leucovorin Recruiting Phase 2
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma [NCT02023333] Stivarga Recruiting Phase 2
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer [NCT02096354] RRx-001, Stivarga Recruiting Phase 2
Study of Ruxolitinib in Colorectal Cancer Patients [NCT02119676] Jakafi, Stivarga Recruiting Phase 2
Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer [NCT01896856] Camptosar, SGI-110, Stivarga Recruiting Phase 1/Phase 2
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer [NCT02168777] Refametinib, Stivarga Recruiting Phase 1/Phase 2
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer [NCT02116894] PF-03446962, Stivarga Recruiting Phase 1
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination [NCT01973868] Erbitux, Stivarga Recruiting Phase 1
Regorafenib and Cetuximab in Patients With Advanced Malignancy [NCT02095054] Erbitux, Stivarga Recruiting Phase 1
Regorafenib + Panitumumab [NCT02199223] Stivarga, Vectibix Recruiting Phase 1
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer [NCT02024607] Avastin, BBI-608, Camptosar, Eloxatin, Fluorouracil, Stivarga, Xeloda, leucovorin Recruiting Phase 1
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment [NCT01853046] Stivarga Recruiting Phase 1
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy [NCT01538680] Stivarga Available N/A


Dear Therapy Finder® User:

During the past two years we have witnessed an unprecedented upswing in research activity leading to the identification of increasing numbers of actionable biomarkers and several effective targeted treatments. To accommodate this dramatic increase in the number of relevant biomarkers, their interactions, and other patient attributes, we are developing a new application design, one that will be both easier to use and more relevant to practicing physicians and patients. This new system will unify many of the best features and key learnings from the Therapy Finders with those from our Genomic Variant Annotation™ (GVA) reporting system.

Until we complete the redesign of our Therapy Finders or offer substitute decision-support products, we are suspending the updating of the Therapy Finders appearing on the CollabRx website and other sites.

If you click through and decide to use the Colon Cancer, Lung Cancer, Melanoma or Metastatic Breast Cancer Therapy Finders, please do so with caution, as some of the data have not been updated since October 15, 2014.

CollabRx, Inc.
July 6, 2015